Literature DB >> 15331580

Minireview: Cyclin D1: normal and abnormal functions.

Maofu Fu1, Chenguang Wang, Zhiping Li, Toshiyuki Sakamaki, Richard G Pestell.   

Abstract

Cyclin D1 encodes the regulatory subunit of a holoenzyme that phosphorylates and inactivates the retinoblastoma protein and promotes progression through the G1-S phase of the cell cycle. Amplification or overexpression of cyclin D1 plays pivotal roles in the development of a subset of human cancers including parathyroid adenoma, breast cancer, colon cancer, lymphoma, melanoma, and prostate cancer. Of the three D-type cyclins, each of which binds cyclin-dependent kinase (CDK), it is cyclin D1 overexpression that is predominantly associated with human tumorigenesis and cellular metastases. In recent years accumulating evidence suggests that in addition to its original description as a CDK-dependent regulator of the cell cycle, cyclin D1 also conveys cell cycle or CDK-independent functions. Cyclin D1 associates with, and regulates activity of, transcription factors, coactivators and corepressors that govern histone acetylation and chromatin remodeling proteins. The recent findings that cyclin D1 regulates cellular metabolism, fat cell differentiation and cellular migration have refocused attention on novel functions of cyclin D1 and their possible role in tumorigenesis. In this review, both the classic and novel functions of cyclin D1 are discussed with emphasis on the CDK-independent functions of cyclin D1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331580     DOI: 10.1210/en.2004-0959

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  332 in total

1.  Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.

Authors:  Manjinder Kaur; Balaiya Velmurugan; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.

Authors:  Omana P Mathew; Kasturi Ranganna; Frank M Yatsu
Journal:  Biomed Pharmacother       Date:  2010-12       Impact factor: 6.529

3.  A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer.

Authors:  Aldema Sas-Chen; Roi Avraham; Yosef Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-12       Impact factor: 2.673

Review 4.  Tight junctions in the testis: new perspectives.

Authors:  Dolores D Mruk; C Y Cheng
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-05-27       Impact factor: 6.237

5.  PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1.

Authors:  Marybeth A Pysz; Olga V Leontieva; Nicholas W Bateman; Joshua M Uronis; Kathryn J Curry; David W Threadgill; Klaus-Peter Janssen; Sylvie Robine; Anna Velcich; Leonard H Augenlicht; Adrian R Black; Jennifer D Black
Journal:  Exp Cell Res       Date:  2009-02-14       Impact factor: 3.905

6.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

7.  Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues.

Authors:  Maria De Falco; Valentina Fedele; Luca De Luca; Roberta Penta; Giuliano Cottone; Ivan Cavallotti; Vincenza Laforgia; Antonio De Luca
Journal:  J Anat       Date:  2004-11       Impact factor: 2.610

8.  Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells.

Authors:  Maria E Gonzalez; Olga Makarova; Esther A Peterson; Lisa M Privette; Elizabeth M Petty
Journal:  Cell Signal       Date:  2008-11-18       Impact factor: 4.315

Review 9.  Potential roles of longan flower and seed extracts for anti-cancer.

Authors:  Chih-Cheng Lin; Yuan-Chiang Chung; Chih-Ping Hsu
Journal:  World J Exp Med       Date:  2012-08-20

10.  Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells.

Authors:  Naveena B Janakiram; Altaf Mohammed; Misty Brewer; Taylor Bryant; Laura Biddick; Stan Lightfoot; Gopal Pathuri; Hariprasad Gali; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.